High Quality 99% Erlotinib Hydrochloride/Erlotinib HCl CAS: 183319-69-9 with Best Price

 Details:

 Use in Cancer:

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

Non-small cell lung cancer (NSCLC).
It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certain

epidermal receptor (EGFR) mutations.
It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.
Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.
Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.

 COA:

Application:

Erlotinib hydrochloride (the trade name Tarceva) is a directly acting inhibitor of epidermal

receptor (EGFR/HER-1) tyrosine kinase with an IC50 of 2 nM.
Epidermalr receptor (EGFR) is one member of the ErbB family which includes EGFR (ErbB1), ErbB2, ErbB3 and ErbB4. The activation of EGFR is dependent on the binding of peptide  to the receptor. In many carcinomas, the presence of EGFR mutation leads to the activation of EGFP, which causes cell proliferation and other cancer processes.
Selective inhibition of EGFR tyrosine kinase by erlotinib hydrochloride leads to the disruption of cancer growth and development which include cell migration, proliferation, angiogenesis, and apoptosis. For instance, erlotinib hydrochloride was shown to induce cell apoptosis and G0/G1 cell cycle arrest in hepatocellular cancer cells, Bxpc-3 and PANC-1 cells, thereby enhancing chemosensitivity towards cytostatics.
In addition, this product is widely researched and used for the treatment of human advanced non-small cell lung cancer (NSCLC). In pancreatic cancer, erlotinib hydrochloride was also reported to exhibit an anti-tumour effect.